Pharsight

Varithena is owned by Provensis.

Varithena contains Polidocanol.

Varithena has a total of 5 drug patents out of which 1 drug patent has expired.

Expired drug patents of Varithena are:

US6846412

Varithena was authorised for market use on 25 November, 2013.

Varithena is available in solution;intravenous dosage forms.

Varithena can be used as a method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities, a method of generating an injectable foam of controlled density and bubble size.

The generics of Varithena are possible to be released after 12 May, 2032.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7731986	PROVENSIS	Therapeutic foam	Nov, 2024 (1 year, 9 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6846412	PROVENSIS	Combination filter assembly	Jul, 2022 (6 months ago)
US8122917	PROVENSIS	Apparatus and method for dispensing foam	Sep, 2024 (1 year, 7 months from now)
US7814943	PROVENSIS	Apparatus and method for dispensing foam	Nov, 2027 (4 years from now)
US9480652	PROVENSIS	Aerosol valve	May, 2032 (9 years from now)

Drugs and Companies using POLIDOCANOL ingredient

Market Authorisation Date: 25 November, 2013

Treatment: A method of generating an injectable foam of controlled density and bubble size; A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities

Dosage: SOLUTION;INTRAVENOUS